Screener
Theravance Biopharma TBPH Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The source filing: Theravance Biopharma’s 10-Q, filed August 11, 2026. Open the filing →
- Filed
- Aug 11, 2026, 8:00 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-093773
FAQ
- What is Theravance Biopharma's retained earnings?
- Theravance Biopharma (TBPH) reported retained earnings of -$870.46M in Q2 2026.
- How has Theravance Biopharma's retained earnings changed year-over-year?
- Theravance Biopharma's retained earnings increased by 5.8% year-over-year, from -$924.27M to -$870.46M.
- What is the long-term trend for Theravance Biopharma's retained earnings?
- Over 5 years (2020 to 2025), Theravance Biopharma's retained earnings has grown at a -10.9% compound annual growth rate (CAGR), from -$1.53B to -$859.63M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.
Ask your AI about Theravance Biopharma's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude